First Affiliated Hospital of Harbin Medical University
Phase
Not applicable
Started
2026-09-18
Last updated
2026-08-28
Condition(s) studied
AISStroke
Investigational drug(s) / intervention(s)
Patients assigned to the EVT group should undergo EVT as soon as possible, followed by BMM according to the current EVT guidelines.The medical group receives BMM alone. EVT is not performed in the medical group.
Patients assigned to the EVT group should undergo EVT as soon as possible, followed by BMM according to the current EVT guidelines.: EVT should be performed as soon as possible in patients randomized to the EVT group. Investigators and clinicians should make every effort to minimize delays related to pre-procedural preparation, with a target interval of no more than 60 minutes from randomization to arterial puncture. EVT in the EVT group can be performed with any thrombectomy device (NMPA approved) usually used at study site.
The medical group receives BMM alone. EVT is not performed in the medical group.: The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to current AIS management guidelines but may NOT include any intra-arterial therapies.
Inclusion Criteria:
1. ≥18 years.
2. Symptoms onset or Time last known well ≤ 24 h from randomization.
3. Acute ischemic stroke due to an occlusion of the intracranial internal carotid artery, M1 or proximal M2 segment of the middle cerebral artery confirmed by CTA or MRA.
4. NCCT or diffusion-weighted imaging (DWI) demonstrating ASPECTS ≤ 2 or infarct core volume (defined as rCBF \<30% on CTP) ≥ 100 mL.
5. Selection imaging performed ≤ 3 hours before randomization.
6. Pre-stroke mRS 0 - 1.
7. Informed consent form was signed.
Exclusion Criteria:
1. Evidence of intracranial hemorrhage on CT/MRI, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, or subdural/epidural hemorrhage.
2. Cerebral midline shift or herniation, or other ventricular mass effect with midline shift as confirmed on CT/MRI.
3. Bilateral anterior circulation or acute multi-vessel occlusion involving both anterior and posterior circulation, confirmed by CTA or MRA.
4. Blood pressure \>185/110 mmHg and is refractory to medicine.
5. Known coagulopathy, with international normalized ratio (INR) \>1.7 or platelet count \<100×10⁹/L;
6. Current treatment with direct thrombin inhibitors or factor Xa inhibitors;
7. Patients with severe organ failure (cardiac, pulmonary, renal, or hepatic);
8. Concomitant malignancy or other conditions with life expectancy under 6 months;
9. Female who is known to be pregnant;
10. Prior endovascular attempt for this stroke;;
11. Currently participation in another clinical study;
12. Other circumstances that the investigator considers inappropriate for participation.
Primary outcome measure(s)
The primary efficacy endpoint is the mRS score at 90 days after randomization. — at 90 days after randomization.
Trial sites (1)
Facility
City
Region
Status
he First Affiliated Hospital of Harbin Medical University
Harbin
Hei Longjiang
More First Affiliated Hospital of Harbin Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.